Alzheimer's Disease Cell Atlas and Data Hub for Integrated Brain Pathology and Omics
Official title: A Research Community Hub and Data Resource for Integrated Neuropathological and Omics Analysis of Alzheimer's disease.
Funded at Allen Institute · NIH-11416723 · Data updated 2026-11-12
A nationwide effort to map brain cells and molecular data in Alzheimer’s and related dementias to create a shared, searchable resource for researchers and patients alike.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Allen Institute NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 1, 2020 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $2,892,122 |
| NIH project number | 5U19AG060909-07 |
| Project ID | NIH-11416723 on NIH RePORTER |
Who could benefit from this research
✓Could help
Researchers and clinicians studying Alzheimer’s disease and related dementias who need integrated cellular, molecular, and clinical data.
✕Less likely to help
Direct patient benefit may be limited to those not involved in research access or when data relevance does not translate to their specific condition.
What this research studies
This project creates a community data hub and atlas focused on Alzheimer’s disease and related dementias, building on large brain-mapping initiatives to catalog cellular and molecular changes. It will organize multi-site, multimodal data from multiple SEA-AD projects into standardized pipelines and secure cloud storage to enable researchers to access and analyze the data. The Data Core will perform integrative computational analysis to model disease progression and identify affected cell types across donors, with an emphasis on translating findings into broader community use. An Integrative Analysis Center will harmonize single-cell data and pathology representations across the AD/ADRD research community to accelerate discoveries. The effort aims to maximize impact by providing a scalable, accessible resource that could inform future diagnostics and therapies for Alzheimer’s disease and related dementias.
Why it matters
Potential benefit: If successful, patients could benefit from faster translation of cellular and molecular insights into improved diagnostics and targeted therapies for Alzheimer’s disease and related dementias.
How similar studies have gone: Prior large-scale brain atlas efforts and multi-omics data hubs have enabled cross-site collaboration and new insights, suggesting potential for meaningful impact here.
Where this research is happening
-
Allen Institute
Seattle, United States Active
Researchers
- Principal investigator: Hawrylycz, Michael — Allen Institute
- Study coordinator: Hawrylycz, Michael
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.